Table 1

Demographic and baseline disease characteristics

Tight control (n=126)Usual care (n=126)p Value*
Age (mean (±SD), years)56 (13)57 (14)0.57
Time since symptoms (median (IQR), weeks)15 (8–26)18 (9–37)0.042
Time since diagnosis (median (IQR), weeks)0 (0–0)0 (0–0)0.99
Women (n (%))78 (62%)77 (61%)0.89
Rheumatoid factor positive (n (%))79 (63%)93 (74%)0.058
Anti-cyclic citrullinic peptide positive (n (%))71 (64%)69 (62%)0.78
DAS28 (mean (SD))5.0 (1.2)4.8 (1.1)0.13
HAQ score (median (IQR))1.1 (0.8–1.5)0.9 (0.5–1.3)0.002
Swollen joint count (median (IQR))8 (5–12)8 (5–12)0.63
Tender joint count (median (IQR))5 (2–10)4 (2–9)0.25
ESR (median (IQR), mm/h)28 (14–44)29 (18–44)0.69
CRP (median (IQR), mg/l)11 (5–34)9 (0–31)0.15
VAS pain, 0–100 (mean (SD), mm)53 (23)45 (22)0.006
VAS GH, 0–100 (mean (SD), mm)53 (24)44 (22)0.003
  • IQR P25–P75.

  • * p value for between group comparisons

  • CRP, C reactive protein; DAS28, Disease Activity Score based on 28 joint counts; ESR, erythrocyte sedimentation rate; GH, general health; HAQ, Health Assessment Questionnaire; VAS, Visual Analogue Scale.